You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Human rights and clinical ethics are the right framework to address the probable DMPA-HIV interaction
  1. Elana Covshoff, MA
  1. Ulrike Sauer, MFSRH
  1. Rudiger Pittrof, * MSc
  1. Health Improvement Practitioner, Guys and St Thomas’ Foundation Trust – Community Services, London, UK; elanacovshoff@gmail.com
  2. Consultant in Sexual and Reproductive Health, Margaret Pyke Centre, Reproductive Health, London, UK; ulrike.sauer@nhs.net
  3. Consultant in Community Sexual Health and HIV, GSTT – Sexual Health, St Thomas’ Hospital, London, UK; Rudiger.Pittrof@gstt.nhs.uk
  1. *Corresponding author.

https://doi.org/10.1136/jfprhc-2015-101176

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We were delighted to read the very timely paper by Haddad et al.1 that has become even more topical with the recent publication of a systematic review showing that depot medroxyprogesterone acetate (DMPA) use is indeed associated with about a 40% increased risk of HIV acquisition (12 studies involving more than 39 500 women, pooled hazard ratio 1·40, 95% confidence interval 1.16–1.69).2 Other forms of hormonal contraception do not appear to increase this risk. In the accompanying press release the lead author, Lauren Ralph, stated: “Banning DMPA would leave many women without immediate access to alternative, effective contraceptive options. This is likely to lead to more unintended pregnancies, and because childbirth remains life-threatening in many developing countries, could …

    View Full Text

    Footnotes

    • Competing interests None.

    Linked Articles